Kristen Ciombor, MD, MSCI

Articles

Role of Tucatinib in HER2+ mCRC

February 27th 2023

Switching their focus to tucatinib, expert panelists review data from the MOUNTAINEER study and define the role of tucatinib in managing HER2+ metastatic colorectal cancer.

HER2+ mCRC: Managing Adverse Events Associated With Antibody Drug Conjugates

February 27th 2023

Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.

Trastuzumab Deruxtecan in HER2+ mCRC

February 20th 2023

Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.

First-Line Treatment Options for mCRC

February 20th 2023

After a brief overview on first-line treatment options for patients with metastatic colorectal cancer, panelists highlight the role HER2 status plays in the selection of novel therapies.

Challenges With Molecular Testing in Metastatic Colorectal Cancer

February 16th 2023

A comprehensive discussion on the barriers to molecular testing in metastatic colorectal cancer, along with challenges in utilizing these tests in the real-world setting.

Circulating Tumor DNA to Guide Treatment Selection for mCRC

February 16th 2023

Panelists consider the potential role for circulating tumor DNA to inform the selection of therapy for patients with metastatic colorectal cancer.

Role of Tissue Versus Circulating Tumor DNA in Molecular Testing in mCRC

February 9th 2023

Shared insight on the value tissue and circulating tumor DNA respectively provide in molecular testing for patients with metastatic colorectal cancer.

Overview of Molecular Testing in Metastatic Colorectal Cancer (mCRC)

February 9th 2023

Experts in metastatic colorectal cancer management highlight the role of molecular testing and testing modalities available in the academic and community settings.

Dr. Ciombor on Rechallenging With EGFR Inhibitors in RAS/RAF Wild-Type CRC

January 7th 2022

Kristen K. Ciombor, MD, MSCI, discusses data evaluating the utility of rechallenging with EGFR inhibitors in RAS/RAF wild-type colorectal cancer.

Dr. Ciombor on the Utilization of Maintenance Panitumumab in RAS Wild-Type Metastatic CRC

December 20th 2021

Kristen K. Ciombor, MD, MSCI, discusses the use of panitumumab in the maintenance treatment of patients with RAS wild-type metastatic colorectal cancer.

Dr. Ciombor on Anti-EGFR Therapy in Metastatic CRC

November 16th 2021

Kristen K. Ciombor, MD, MSCI, discusses the use of anti-EGFR therapy for the frontline treatment of patients with metastatic colorectal cancer.

Dr. Ciombor on the Efficacy of Preoperative Chemoradiation in Rectal Cancer

February 17th 2021

Kristen K. Ciombor, MD, MSCI, discusses responses achieved with preoperative chemoradiation in patients with rectal cancer.

Dr. Ciombor on Ongoing Research Efforts in Rectal Cancer

February 11th 2021

Kristen K. Ciombor, MD, MSCI, discusses ongoing research efforts being made in rectal cancer.

Dr. Ciombor on Sequencing Therapies in Locally Advanced Rectal Cancer

February 2nd 2021

Kristen K. Ciombor, MD, MSCI, discusses sequencing treatment options for patients with locally advanced rectal cancer.

Dr. Ciombor on the FDA Approval of Trastuzumab Deruxtecan in HER2+ Metastatic Gastric Cancer

January 22nd 2021

Kristen K. Ciombor, MD, MSCI, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic gastric cancer.

Dr. Ciombor on the Goals of the COLOMATE Trial in mCRC

January 31st 2020

Kristen Ciombor, MD, MSCI, assistant professor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, discusses the goals of the COLOMATE protocol in metastatic colorectal cancer (mCRC).

Dr. Ciombor Discusses Role of Liquid Biopsies in CRC

April 22nd 2019

Kristen Ciombor, MD, MSCI, assistant professor of medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, discusses the role of liquid biopsies in colorectal cancer.